[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	例数	端粒酶（ng/mL）	M2-PK（U/mL）	乳酸（mol/L）
结核性胸腔积液组	30	0.58±0.41	7.78±4.15	2.25±1.71
恶性胸腔积液组	30	2.55±1.72	29.12±3.71	9.45±3.31

组别	例数	端粒酶（ng/mL）	M2-PK（U/mL）	乳酸（mol/L）
结核性胸腔积液组	30	0.58±0.41	7.78±4.15	2.25±1.71
恶性胸腔积液组	30	2.55±1.72	29.12±3.71	9.45±3.31

组别	例数	TE		M2-PK		乳酸
组别	例数	阳性	阴性	阳性	阴性	阳性	阴性
结核性胸腔积液组	30	2（6.7）	28（93.3）	4（13.3）	26（86.7）	5（16.7）	25（83.3）
恶性胸腔积液组	30	24（80.0）	6（20.0）	23（76.7）	7（23.3）	20（66.7）	10（36.3）

组别	例数	TE		M2-PK		乳酸
组别	例数	阳性	阴性	阳性	阴性	阳性	阴性
结核性胸腔积液组	30	2（6.7）	28（93.3）	4（13.3）	26（86.7）	5（16.7）	25（83.3）
恶性胸腔积液组	30	24（80.0）	6（20.0）	23（76.7）	7（23.3）	20（66.7）	10（36.3）

指标	阳性数（例）	敏感性（%）	特异性（%）
TE	24	80.0	76.7
M2-PK	23	76.7	86.7
乳酸	20	66.7	83.3
TE+M2-PK+乳酸	27	90.0	96.9

RichHTML

PDF (PC)

[1]	MIZUKOSHI E,NAKAMOTO Y,MARUKAWA Y,et al.Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma[J]. Hepatology,2006,43(6):1284-1294.
[2]	SHARPLESS N E,DEPINHO R A.Telomeres,stem cells,senescence,and cancer[J]. J Clin Invest,2004,113(2):160-168.
[3]	CHRISTOFK H R,VANDER HEIDEN M G,HARRIS M H,et al.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J].Nature,2008,452(7184):230-233.
[4]	CHEN M,DAVID C J,MANLEY J L.Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins[J]. Nat Struct Mol Boil,2012,19(3):346-354.
[5]	PEDERSEN P L,MATHUPALA S,REMPEL A,et al.Mitochondrial bound type Ⅱ hexokinase:a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention[J].Biochim Biophys Acta,2002,1555(1-3):14-20.